NSE/SANOFI

SANOFISanofi India Ltd

Healthcare · NSE

₹3,559.8-0.03%

52-wk low52-WEEK RANGE52-wk high

₹3,190.9+11.6% from low ·-45.8% from high₹6,569.5

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

SANOFI-41.06% · 1Y

Range high ₹6,717Range low ₹3,160Latest ₹3,559.8252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareSmallcap

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite50/100

Performance

—

Not enough price history to score.

Valuation

Medium

Valuation close to the sector median.

· P/E 25.1 vs sector median 37.8 — 34% cheaper
· P/B 10.92 above sector median

Growth

Low

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeB(69/100)

Durability

A+

100/100

Financially resilient — strong quality + solvency profile.

Show 2 drivers

Debt/Equity0.02 (100pt)
ROE40.6% (100pt)

Valuation

69/100

Fairly priced — not a bargain, not stretched.

Show 4 drivers

P/E vs sector (25.1 / 37.8)66% (100pt)
P/B10.92 (22pt)
Dividend yield6.74% (100pt)
EV/EBITDA16.4 (40pt)

Momentum

38/100

Momentum is muted; trend is unclear or rolling over.

Show 4 drivers

DMA-trend alignmentdown (25pt)
RSI (14)55.0 (60pt)
Price vs 200-DMA-22.0% (18pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)25.06

UNDERVALUED

CheapestP/E 25.1 at 29th %ile of sector — cheaper than 71% of peers.Most expensive

P/B10.92

OVERVALUED

CheapestP/B 10.92 at 92th %ile of sector.Most expensive

EV/EBITDA16.36

FAIR

Monthly seasonality

Avg monthly return over 10 years · historical — not a forecast

Best: Jul +3.02% · Worst: Sep -2.80%

Jan

-2.4%

30% win

Feb

+0.2%

50% win

Mar

-1.6%

40% win

Apr

+0.8%

40% win

May

+2.2%

50% win

Jun

-1.0%

Monthly return distribution

Distribution of 120 monthly returns

Mean

+0.08%

Median

+0.27%

Std dev

7.15%

Best

+24.4%

Worst

-24.7%

% positive

53%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 4

High-quality compounder (ROE 40.6%)
Above 20% ROE consistently flags capital-efficient businesses
Lean balance sheet (D/E 0.02)
Low leverage means earnings are less sensitive to rate cycles
Strong net margin (17.8%)
High margin indicates pricing power + operating efficiency
Top quartile ROE in Healthcare
Rank 1 of 24 peers

WEAKNESSES · 1

Revenue contracting (-8.7% YoY)
Negative top-line growth is the hardest signal to overcome

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 1

Profit contracting sharply (-21.0% YoY)
Double-digit earnings decline pressures valuation compression

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

-0.0%

+1.9%

+1.7%

-14.4%

-24.3%

-42.4%

-14.3%

-15.3%

10Y

-1.8%

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
SANOFITHIS Sanofi India Limited	₹3,559.8	-43.6%	8,187	25.1	10.92	40.6%	0.02	-8.7%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
APOLLOHOSP Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%

ASK AXEL

Dig deeper into SANOFI

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for SANOFI — all in one sourced reply.

Ask free in chat

Run these tools on SANOFI

Historical return →

"If I had bought SANOFI in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on SANOFI

Brokerage + charges →

All-in cost for trading SANOFI

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Date	Amount
2025-11-07	₹75.00
2025-04-25	₹117.00
2024-05-03	₹117.00
2024-03-07	₹50.00
2023-04-28	₹377.00
2022-08-05	₹193.00
2022-04-12	₹490.00
2021-04-19	₹365.00
2020-06-29	₹349.00
2019-04-25	₹66.00
2018-08-06	₹18.00
2018-04-26	₹53.00
2017-07-31	₹18.00
2017-04-25	₹50.00
2016-08-04	₹18.00

SANOFISanofi India Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Peer comparison · Healthcare

Ask Axel about SANOFI

Recent news

Dig deeper into SANOFI

Run these tools on SANOFI

Technical snapshot

Dividends + splits history

SWOT analysis

Recent news

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Stock scorecard

Fundamentals

Pros and cons

Sector-relative context

Peer comparison · Healthcare